SCHEMBL25166373

SCHEMBL25166373

Clc1cc(C2=CCCCC2)nc(Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
TYMP P19971 1/20 0.35
PSMB5 P28074 9/20 0.35
PSMB1 P20618 1/20 0.34
PDE8A O60658 1/20 0.33
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
ATR Q13535 1/20 0.31
ELANE P08246 1/20 0.31
ACMSD Q8TDX5 1/20 0.30
TRPV3 Q8NET8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29064919 0.83 HSP90AB1 (0.45) TDP1CASP3SENP8SENP7SENP6
SCHEMBL3205153 0.81 HSP90AB1 (0.44) TDP1CASP3SENP8SENP7SENP6
SCHEMBL25166338 0.79 TDP1 (0.40) TDP1CASP3SENP8SENP7SENP6
SCHEMBL25166327 0.79 TDP1 (0.40) TDP1CASP3SENP8SENP7SENP6
SCHEMBL25653229 0.75 TDP1 (0.49) TDP1CASP3SENP8SENP7SENP6
SCHEMBL19531947 0.74 TDP1 (0.37) TDP1CASP3SENP8SENP7SENP6
SCHEMBL19531950 0.74 TDP1 (0.37) TDP1CASP3SENP8SENP7SENP6
SCHEMBL30295725 0.74 TDP1 (0.36) TDP1CASP3SENP8SENP7SENP6
SCHEMBL29064935 0.74 TDP1 (0.36) TDP1CASP3SENP8SENP7SENP6
SCHEMBL25729525 0.71 TDP1 (0.45) TDP1CASP3SENP8SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 CN disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 TDP1 1168/4885CASP3 4397/4885SENP8 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.